Lv3
220 积分 2022-02-09 加入
Results from a Phase II trial (AIRLEAF) of a cathepsin C (dipeptidyl peptidase 1) inhibitor, BI 1291583, in adults with non-cystic fibrosis bronchiectasis*
11个月前
已关闭
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
11个月前
已完结
WS19.05 A Phase II trial (CLAIRAFLY) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase 1 inhibitor BI 1291583 in adults with bronchiectasis due to cystic fibrosis
11个月前
已关闭
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
11个月前
已完结
A profile of brensocatib for non-cystic fibrosis bronchiectasis
11个月前
已完结
Targeting Neutrophilic Inflammation in Obstructive Airway Disease - A Narrative Review of Brensocatib Therapy
11个月前
已完结
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease
11个月前
已完结
In patients with bronchiectasis, daily brensocatib reduced annualized pulmonary exacerbation rates
11个月前
已完结
What is brensocatib?
11个月前
已关闭
BRINSUPRI (brensocatib)
11个月前
已关闭
皖公网安备34019202002308
